Positive Outlook for Opus Genetics: Regulatory Support and Financial Stability Justify Buy Rating

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Opus Genetics. The associated price target remains the same with $8.00.

Yun Zhong’s rating is based on several key factors that highlight the promising outlook for Opus Genetics. The positive feedback from the FDA regarding the Phase 3 plan for OPGx-LCA5 indicates strong regulatory support for an expedited pathway, addressing an urgent unmet medical need. This is further supported by promising data reported by the company thus far. The adaptive design of the study is a significant feature, providing flexibility and efficiency in the clinical trial process.
Additionally, the enrollment of the first patient at a new clinical site in Texas and the preparation for commercial scale manufacturing are underway, indicating progress in the company’s plans. The use of an LCA5 patient registry aims to streamline patient identification and enrollment, with the goal of starting dosing in the second half of 2026. Financially, the proceeds from a recent direct offering are expected to support operations until the second half of 2027, providing a solid runway for the company. These regulatory and financial updates collectively contribute to a positive outlook for the OPGx-LCA5 program, justifying the Buy rating.